Plasma fluphenazine levels and clinical response in newly admitted schizophrenic patients

T. Van Putten, M. Aravagiri, S. R. Marder, W. C. Wirshing, J. Mintz, N. Chabert

Research output: Contribution to journalArticlepeer-review

11 Scopus citations

Abstract

Seventy-two newly readmitted, drug-free men with the diagnosis of schizophrenia by DSM-III were assigned randomly to receive fluphenazine hydrochloride at 5 mg, 10 mg, or 20 mg daily for 4 weeks. Fluphenazine (FLU), fluphenazine sulfoxide, 7-hydroxyfluphenazine, and fluphenazine N-oxide were measured by highly specific and sensitive radioimmunoassays. Data were analyzed by logistic regression using the Clinical Global Impressions Disabling Side Effects and Global Improvement as the outcome measures. Disabling side effects were defined as 'side effects that significantly interfered with patient's functioning' or 'side effects that outweigh therapeutic effects' (National Institute of Mental Health 1985, p. 839). Higher plasma FLU levels (up to 4.23 ng/mL) were significantly (p = .015) associated with a higher rate of global improvement. However, close to 90 percent of these acute patients had disabling side effects at a plasma FLU level of 2.7 ng/mL. At least in the patient's view, these disabling side effects negated or compromised the improvement in psychosis. Fluphenazine N-oxide may be a toxic metabolite in that it was more powerfully associated with side effects than was the parent FLU.

Original languageEnglish (US)
Pages (from-to)91-96
Number of pages6
JournalPsychopharmacology bulletin
Volume27
Issue number2
StatePublished - 1991
Externally publishedYes

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Plasma fluphenazine levels and clinical response in newly admitted schizophrenic patients'. Together they form a unique fingerprint.

Cite this